10/542870

=> s 111

SAMPLE SEARCH INITIATED 15:30:40 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80 PROJECTED ANSWERS: 1 TO 80

L12 1 SEA SSS SAM L11

=> s ll1 sss ful

FULL SEARCH INITIATED 15:30:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 31 TO ITERATE

100.0% PROCESSED 31 ITERATIONS 10 ANSWERS

SEARCH TIME: 00.00.01

L13 10 SEA SSS FUL L11

=> file caplus

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST
166.94
762.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION

CA SUBSCRIBER PRICE 0.00 -36.00

FILE 'CAPLUS' ENTERED AT 15:30:57 ON 04 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Mar 2006 VOL 144 ISS 11 FILE LAST UPDATED: 3 Mar 2006 (20060303/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 113

L14 1 L13

=> d l14 bib abs hitstr

```
C:\Documents and Settings\EBernhardt\My Document
                                                                      13-23
chain nodes :
```

```
11 12 13 14 23 24 25 26 27 29
ring nodes :
    1 2 3 4 5 6 7 8 9 10 15 16 17 18 19 20
chain bonds :
    7-11 8-14 9-29 11-12 11-13 13-23 14-16 19-24 24-25 25-26 25-27
ring bonds :
    1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 15-16 15-20 16-17 17-18
18-19 19-20
exact/norm bonds :
    9-29 11-12 11-13 13-23 14-16 15-16 15-20 16-17 17-18 18-19 19-20 19-24 25-26
25-27
exact bonds :
    7-11 8-14 24-25
normalized bonds :
    1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10
```

G1:0,N

```
Match level:
```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom

23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 29:Atom

```
L14
      ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
ΑN
      2004:648345 CAPLUS
DN
      141:190803
ΤI
      Preparation of quinoline derivatives as NK-2 and NK-3 receptor antagonists
IN
      Kerns, Jeffrey; Jin, Qi; Wan, Zehong; Nie, Hong; Zhu, Chongjie
PA
      Smithkline Beecham Corporation, USA
      PCT Int. Appl., 53 pp.
SO
      CODEN: PIXXD2
DT
      Patent
      English
LA
FAN.CNT 1
      PATENT NO.
                              KIND
                                       DATE
                                                      APPLICATION NO.
                                                                                   DATE
                               - - <del>-</del> -
                                                      -----
                                       -----
      WO 2004066950
PΙ
                                A2
                                       20040812
                                                      WO 2004-US2366
                                                                                   20040129
      WO 2004066950
                                Α3
                                       20041104
           W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
               CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
      EP 1601360
                                A2
                                       20051207 EP 2004-706434
                                                                                20040129
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI US 2003-443650P
                               Ρ
                                       20030130
      WO 2004-US2366
                                W
                                       20040129
      MARPAT 141:190803
os
GI
```

$$R^1$$
 R^2
 N
 R^3
 R^4
 N
 R^7
 R^7
 R^7
 R^7
 R^7
 R^7
 R^7
 R^7

AB The title compds. [I; R1 = H, (un) substituted alkyl; R2 = (un) substituted aryl, cycloalkyl, heterocyclyl; R3 = H, (un)substituted alkyl, cycloalkyl, aryl, heterocyclyl; A = NR8, O (R8 = H, (un) substituted alkyl); R4 = (un) substituted heterocyclyl; R5 = H, alkyl, alkenyl, aryl, etc.; or R5 represents a bridging moiety which is arranged to bridge two adjacent ring atoms, wherein the bridging moiety comprises alkylene or dioxyalkylene; R6 = H, halo; R7 = oxo; n = 1-4] which are NK2 and NK3 receptor antagonists and are useful in the treatment of respiratory diseases, were prepd. E.g., a 4-step synthesis of 3-(4-dimethylcarbamoylmethyl-3-oxopiperazin-1ylmethyl) -2-(thiophen-2-yl)quinoline-4-carboxylic acid [(S)-1-cyclohexylethyl]amide, was given. The most potent compds. I show IC50 in the range 10-1000 nM against NK-3 receptor binding, and IC50 in the range 1-1000 nM against NK-2 receptor binding. The pharmaceutical compn. comprising the compd. I is claimed. 737804-27-2P 737804-30-7P 737804-36-3P IT

CN

737804-40-9P 737804-41-0P 737804-42-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of quinoline derivs. as NK-2 and NK-3 receptor antagonists for treating respiratory diseases)

RN 737804-27-2 CAPLUS

4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[2-(dimethylamino)-2-oxoethyl]-3-oxo-1-piperazinyl]methyl]-2-(2-thienyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737804-30-7 CAPLUS

4-Quinolinecarboxamide, 3-[[4-(2-amino-2-oxoethyl)-3-oxo-1-piperazinyl]methyl]-N-[(1S)-1-cyclohexylethyl]-2-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN

RN 737804-36-3 CAPLUS

CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[2-(dimethylamino)-2-oxoethyl]-2-oxo-1-piperazinyl]methyl]-2-(2-thienyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737804-40-9 CAPLUS

CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[2-[[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]amino]-2-oxoethyl]-3-oxo-1-piperazinyl]methyl]-2-(2-thienyl)- (9CI) (CA INDEX NAME)

RN 737804-41-0 CAPLUS

CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[2-[[(4-methyl-1H-imidazol-2-yl)methyl]amino]-2-oxoethyl]-3-oxo-1-piperazinyl]methyl]-2-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737804-42-1 CAPLUS

CN 4-Quinolinecarboxamide, N-[(1S)-1-cyclohexylethyl]-3-[[4-[2-[methyl(2-thienylmethyl)amino]-2-oxoethyl]-3-oxo-1-piperazinyl]methyl]-2-(2-thienyl)-(9CI) (CA INDEX NAME)

IT 737804-43-2P 737804-46-5P 737804-47-6P 737804-48-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of quinoline derivs. as NK-2 and NK-3 receptor antagonists for treating respiratory diseases)

RN 737804-43-2 CAPLUS

CN 1-Piperazineacetic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-(2-thienyl)-3-quinolinyl]methyl]-2-oxo-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737804-46-5 CAPLUS

CN 1-Piperazineacetic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-(2-thienyl)-3-quinolinyl]methyl]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)

10/542870

RN 737804-47-6 CAPLUS

CN 1-Piperazineacetic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-2-(2-thienyl)-3-quinolinyl]methyl]-3-oxo-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737804-48-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[[4-[[[(1S)-1-cyclohexylethyl]amino]carbonyl]-6-fluoro-2-(2-thienyl)-3-quinolinyl]methyl]-2-oxo- (9CI) (CA INDEX NAME)

=> file caold COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 5.57 768.06 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -0.75 -36.75

FILE 'CAOLD' ENTERED AT 15:31:14 ON 04 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l13 L15 0 L13

=> log h

10/542870

| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
|--------------------------------------------|------------|---------|
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.44 | 768.50 |
| | | |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | 0.00 | -36.75 |

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:31:21 ON 04 MAR 2006

EAST Search History

| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|----------|------|--------------------------------|--------------------|---------------------|---------|------------------|
| L1 | 1594 | ((544/121) or (544/357)).CCLS. | US-PGPUB; USPAT | OR | OFF | 2006/03/04 21:12 |
| L2 | 465 | NK-2 or NK-3 | US-PGPUB; USPAT | OR | OFF | 2006/03/04 21:12 |
| L3 | 8 | l1 and l2 | US-PGPUB; USPAT | OR | OFF | 2006/03/04 21:12 |

3/4/06 9:13:44 PM Page 1